Vion Pharmaceuticals
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Vion Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#772 of 15,742 sponsors by registered trial count).
Vion Pharmaceuticals: 19 sponsored US clinical trials, none currently recruiting.
Vion Pharmaceuticals sponsors 19 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 19 completed. 1 of these trials are in Phase 3-4 (later-stage) and 18 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Unspecified Adult Solid Tumor, Protocol Specific, with 2 trials.
Top-decile sponsor footprint
Vion Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#772 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
19 of 19 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
19 total, page 1 of 1
VNP40101M in Treating Patients With Acute Myelogenous Leukemia or High-Risk Myelodysplasia
NCT00083187
VNP40101M in Treating Patients With Relapsed or Refractory Locally Advanced or Metastatic Small Cell Lung Cancer
NCT00282022
VNP40101M in Treating Patients With Richter Syndrome or Refractory or Relapsed Chronic Lymphocytic Leukemia or Other Lymphoproliferative Disorders
NCT00304005
Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia
NCT00112554
Temozolomide and VNP40101M in Treating Patients With Relapsed or Refractory Leukemias
NCT00098436
VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies
NCT00070538
3-AP and Cytarabine in Treating Patients With Hematologic Cancer
NCT00064090
3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer
NCT00064051
3-AP and Gemcitabine in Treating Patients With Metastatic Non-Small Cell Lung Cancer
NCT00064064
3-AP in Treating Patients With Advanced Prostate Cancer
NCT00054015
VNP40101M in Treating Patients With Advanced or Metastatic Cancer
NCT00049699
VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome
NCT00049686
Combination Chemotherapy in Treating Patients With Advanced Cancer
NCT00024323
VNP40101M in Treating Patients With Advanced Solid Tumors or Lymphomas
NCT00025129
3-AP Plus Cisplatin and Paclitaxel in Treating Patients With Advanced or Metastatic Cancer
NCT00016874
VNP20009 in Treating Patients With Advanced Solid Tumors
NCT00006254
3-AP in Treating Patients With Advanced Cancer
NCT00006218
VNP20009 in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Therapy
NCT00004216
3-Aminopyridine-2-carboxaldehyde Thiosemicarbazone in Treating Patients With Solid Tumors
NCT00004213
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 13 |
| Phase 2 | 5 |
| Phase 3 | 1 |
Therapeutic Areas
How the Vion Pharmaceuticals early-phase archive is shaped
19 indexed studies, none listed as recruiting (0% open); 19 completed (100%).
Phase mix: 1 late (III/IV) vs 18 early (I/II) (early-phase heavy).
Top condition: Unspecified Adult Solid Tumor, Protocol Specific (2 trials), 4 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Vion Pharmaceuticals: archived-pipeline peers nationwide
Peers matched on 19 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Vion Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 19 archived trials
- Almirall, S.A. · 19 trials · 5% recruiting
- Bastyr University · 19 trials · 11% recruiting
- Church & Dwight Company · 19 trials · 0% recruiting
- Cordis US · 19 trials · 5% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Vion Pharmaceuticals page
19 registered trials is a research-attention snapshot, not an endorsement of Vion Pharmaceuticals or any single study.
- None of Vion Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Unspecified Adult Solid Tumor, Protocol Specific is the condition Vion Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Unspecified Adult Solid Tumor, Protocol Specific trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Vion Pharmaceuticals pipeline card: 19 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.